Core Viewpoint - YXH (One Heart Hall) is undergoing a transformation to adapt to changing market conditions and consumer preferences, focusing on enhancing its product offerings and operational efficiency [6][5]. Group 1: Company Overview - YXH's main business includes pharmaceutical retail chains and pharmaceutical distribution [6]. - In Q1 2025, YXH reported a total revenue of 4.767 billion yuan, a year-on-year decrease of 6.53%, and a net profit attributable to shareholders of 160 million yuan, down 33.83% [6]. Group 2: Business Strategy and Transformation - The company has no specific restrictions on non-pharmaceutical sales in its operating regions, allowing flexibility in product offerings [2]. - All stores are required to undergo transformation to meet the evolving market demands, with a classification into specialized pharmacies (over 20%) and multi-category pharmacies (over 70%) [3]. - The transformation strategy includes increasing product variety and enhancing employee skills, with minimal financial impact due to the focus on optimizing existing space rather than large-scale investments [5]. Group 3: Financial Performance and Forecast - The company's gross profit margin stands at 31.84%, with a debt ratio of 54.76% [6]. - Recent institutional ratings show 5 buy ratings and 1 hold rating, with an average target price of 17.45 yuan [7]. - Profit forecasts for 2025 predict a net profit of approximately 630 million yuan, with growth expected in subsequent years [9].

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-039 号 一心堂药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动情况介绍 一心堂药业集团股份有限公司（以下简称"公司"）于2025年5月20日、5月21日连续两个 交易日收盘价格涨幅偏离值累计超过20%，根据深圳证券交易所交易规则等有关规定，属于股票 交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票交易异常波动，公司进行了自查，并对相关事项进行了核查，现将有关情况 说明如下： 重大信息。 处于筹划阶段的重大事项。 三、是否存在应披露而未披露信息的说明 公司于2025年4月25日召开第六届董事会第十四次会议，会议决议于2025年5月21日下午14 时在公司会议室召开公司2024年年度股东会。2025年5月21日上午，有投资者到公司实地调研， 公司管理层就投资者关心的问题进行交流，公司将公告投资者调研会议记录。公司董事会确认， 除上述情况外，本公司目前没有任何根据《深圳证券交易所股票上市规则》等有关规定应予以 披露而未披露的事 ...

证券代码：002727 证券简称：一心堂 投资者关系活动记录表 一心堂药业集团股份有限公司投资者关系活动记录表 编号：TG202505-003 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 路演活动 ☑现场参观 □其他（电话会议） 参与单位名称及人员 姓名 交银基金周章庆、中海基金 易小金、国投瑞银 张宇初、 巨彬资产 何川、景顺长城 王玉、泉果基金 夏若瑜、东北 证券 文将儒、中信建投 沈兴熙、诚域基金 莫景全 黄登 峰等投资者共 16 人。 时间 2025 年 5 月 21 日 10:30-12:00 地点 一心堂药业集团股份有限公司总部 公司接待人员姓名 集团董事兼执行总裁张勇先生、董事郭春丽女士、董事兼 副总裁阮国伟先生、副总裁兼董事会秘书李正红先生、集 团非药品事业部总经理肖勇先生、集团非药品事业部非药 推广部总监刘骏先生、云南公司副总经理谢建兵先生、证 券事务代表阴贯香女士 投资者关系活动主要 内容介绍 一心堂投资者交流活动 附件清单（如有） 投资者调研会议记录 日期 2025 年 5 月 21 日 星期三 1 ...

证券代码：603233 证券简称：大参林 公告编号：2025-031 大参林医药集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 5 月 20 日 (二) 股东大会召开的地点：广州市荔湾区龙溪大道 410 号大参林集团综合楼 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 份总数的比例（%） 77.8557 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，经过半数董事推举，由董事柯国强主持本次股 东大会。会议采取现场投票及网络投票方式召开并表决。会议的召集和召开符合 《公司法》《上市公司股东会规则》和《公司章程》等有关规定。 (五) 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一) 非累积投票议案 审议结果：通过 表决情况： 股东类型 同意 反对 弃权 票数 比例 票数 比例 票数 比例 （%） （%） （ ...

投资者关系活动记录表 证券代码：002727 证券简称：一心堂 一心堂药业集团股份有限公司投资者关系活动记录表 编号：TG202505-002 | | □特定对象调研 | | | | □分析师会议 | | --- | --- | --- | --- | --- | --- | | | □媒体采访 | | | |  业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | | | | 路演活动 | | | □现场参观 | | | | | | | □其他（电话会议） | | | | | | 参与单位名称及人员 | 通过全景网"投资者关系互动平台"(https://rs.p5w.net) | | | | | | | 参与"2024 年度云南辖区上市公司投资者网上集体接待日" | | | | | | 姓名 | 的全体投资者 | | | | | | 时间 | 2025 5 月 | 年 | 16 | 日 | 16:00-17:00 | | 地点 | 全景网"投资者关系互动平台"（http://rs.p5w.net） | | | | | | 公司接待人员姓名 | 副总裁兼董事会秘书李正红先生、证券事务代表阴贯香女 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-037 号 一心堂药业集团股份有限公司 关于全资子公司广西鸿翔一心堂药业有限责任公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一心堂药业集团股份有限公司(以下简称"公司")本次为全资子公司广西鸿翔一心堂药业 有限责任公司(以下简称"广西一心堂"或"债务人")提供连带责任保证方式的担保，被担保 企业广西一心堂最近一期经审计（2024年12月31日）的资产负债率超过70%，敬请投资者充分关 注担保风险。 一、担保情况概述 公司于 2024 年 11 月 26 日召开第六届董事会第十二次会议，于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同意子公司向相关银行申请综合授信额度并为其提 供担保的议案》，同意公司担保下属子公司向相关银行申请综合授信共计 13.68 亿元，用于子 公司融资业务，具体额度在不超过 13.68 亿元的金额上限内以银行授信为准，以上综合授信在 一年内以银行授信为准。 ...

Core Insights - The article discusses the consumer complaint statistics for April 2025 in Yiyuan County, highlighting the total number of complaints and the types of issues faced by consumers [1] Group 1: Overall Complaint Statistics - In April 2025, Yiyuan County's market supervision bureau received a total of 289 consumer complaints, with 252 related to products and 37 related to services [1] - The total disputed amount was 237,300 yuan, with consumers recovering 50,000 yuan in economic losses [1] Group 2: Business Complaint Statistics - The top businesses with the highest complaint volumes included Shandong Chenghe Commercial Co., Ltd. with 5 complaints, and Yiyuan County Yuzhen E-commerce Studio with 4 complaints [2] - The overall mediation success rate for these businesses was 100% [2] Group 3: Product Complaint Statistics - The leading category for product complaints was "Other Goods" with 106 complaints, followed by food with 75 complaints [3][5] - Other categories included home goods and special equipment, each with 9 complaints, and transportation tools with 8 complaints [5] Group 4: Service Complaint Statistics - For service-related complaints, "Other Services" topped the list with 9 complaints, while dining and accommodation services each had 7 complaints [6] - Sales services also recorded 7 complaints [6]

Core Viewpoint - The article discusses the increasing convenience of medical insurance settlement through digital means, particularly the controversial push for facial recognition technology in pharmacies and healthcare facilities, which has raised concerns about privacy and compliance with legal standards [1][4][10]. Group 1: Convenience of Medical Insurance Settlement - Medical insurance settlement is becoming more convenient, evolving from physical cards to electronic codes and now to facial recognition for payment [1]. - The push for facial recognition is part of a broader digital transformation aimed at facilitating access for elderly and less tech-savvy individuals [4][10]. Group 2: Issues with Mandatory Facial Recognition - Reports indicate that some pharmacies and community health service stations are requiring patients to use facial recognition, with claims that it is a new regulation [3][4]. - Complaints have emerged from various regions, including Zhejiang, Jiangsu, and Shanghai, where patients have been told that they cannot proceed without facial recognition [4][10]. Group 3: Performance Metrics and Pressure on Healthcare Workers - Some healthcare facilities have set hard targets for the usage rate of electronic medical insurance codes, linking these metrics to employee performance evaluations [4][10]. - A healthcare worker revealed that if the electronic medical insurance code usage does not meet the required percentage, it could negatively impact their performance assessment and financial incentives [10]. Group 4: Legal and Ethical Concerns - The practice of mandatory facial recognition is legally questionable, as it violates regulations protecting sensitive personal information [10][11]. - New regulations emphasize that facial recognition should not be the only option available and that patients must be informed and give explicit consent [10][11].

Group 1: Financial Performance - In 2024, the company achieved total revenue of 18 billion yuan, a growth of 3.57% compared to 2023, with a net profit of 114 million yuan, a decline of 79.23% from 2023 [5] - In Q1 2025, total revenue reached 4.767 billion yuan, an increase of 8.06% from Q4 2024, with a net profit of 160 million yuan, up 189.74% from Q4 2024 [5] Group 2: Debt Management - As of December 31, 2022, the debt-to-asset ratio was 53.47%, which slightly decreased to 52.68% by December 31, 2023, and increased to 54.53% by December 31, 2024, indicating a manageable level of debt [4] Group 3: Market Strategy and Competition - The company is actively transforming its physical stores to adapt to the competition from online pharmaceutical platforms, focusing on digital transformation and service upgrades [2] - The new retail segment saw a growth of 47.6% in 2024, with O2O instant retail channels contributing 78.2% to this growth [11] - The company plans to expand its store network primarily in the Southwest and South China regions while maintaining a presence in North China [16] Group 4: Industry Outlook - The pharmaceutical retail industry is undergoing rapid consolidation, with an emphasis on improving operational management quality [7] - The company is focusing on professional pharmacy development and diversifying product offerings to cater to younger consumers [10][14] Group 5: Regulatory and Compliance - The company is continuously optimizing its store operations and compliance management in response to regulatory pressures, ensuring sustainable growth [19]

投资者关系活动记录表 | | □特定对象调研 | | | | □分析师会议 | | --- | --- | --- | --- | --- | --- | | | □媒体采访 | | | | 业绩说明会  | | 投资者关系活动类别 | □新闻发布会 | | | | 路演活动 | | | □现场参观 | | | | | | | □其他（电话会议） | | | | | | 参与单位名称及人员 | 全景网"投资者关系互动平台"（http://rs.p5w.net）参 | | | | | | 姓名 | 与本次年度业绩说明会的广大投资者 | | | | | | 时间 | 2025 5 日 | 年 | 月 | 13 | 15:00-17:00 | | 地点 | 全景网"投资者关系互动平台"（http://rs.p5w.net） | | | | | | 公司接待人员姓名 | 董事长兼总裁阮鸿献先生、董事兼执行总裁张勇先生、独 立董事龙小海先生、副总裁兼董事会秘书李正红先生和财 | | | | | | | 务负责人肖冬磊先生 | | | | | | 投资者关系活动主要 | 公司 2024 | | | | 年度网上业绩说 ...